SCHEMBL24307348

SCHEMBL24307348

COCCN1CCN(CC2CCN(C)CC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.41
CACNA2D1 P54289 1/20 0.40
CACNA1B Q00975 1/20 0.40
CACNB1 Q02641 1/20 0.40
CACNA1C Q13936 1/20 0.40
HSD11B1 P28845 1/20 0.39
HRH3 Q9Y5N1 1/20 0.37
GBA1 P04062 2/20 0.37
CHRM5 P08912 1/20 0.36
ADRA2C P18825 1/20 0.36
ACHE P22303 1/20 0.36
NPC1 O15118 1/20 0.36
BDKRB1 P46663 1/20 0.35
KDM1A O60341 1/20 0.35
GSK3B P49841 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26376368 0.86 ACHE (0.38) HSD11B1CHRM5ADRA2CACHENPC1
SCHEMBL26706436 0.86 HSD11B1 (0.37) HSD11B1HRH3GBA1CHRM5ADRA2C
SCHEMBL19977416 0.84 GBA1 (0.34) NCF1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL20322560 0.84 GBA1 (0.34) NCF1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL25571706 0.84 NCF1 (0.54) NCF1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL23173902 0.84 NCF1 (0.54) NCF1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL23205159 0.84 HTR2A (0.40) NCF1CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL24480768 0.84 ACHE (0.56) HRH3ACHEKDM4EALDH1A1
SCHEMBL21664721 0.83 HSD11B1 (0.35) HSD11B1HRH3GBA1CHRM5ADRA2C
SCHEMBL29323014 0.83 HSD11B1 (0.35) HSD11B1HRH3CHRM5ADRA2CACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2023-11-02 US disclosed
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2023-11-02 US disclosed
EP-4186904-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF Ubix Therapeutics, Inc. (KR) 2023-05-31 EP disclosed
WO-2022078470-A1 METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF AR, NR5A1, SHBG NCF1 3023/4885CACNA2D1 3809/4885CACNA1B 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.